📣 VC round data is live. Check it out!
- Public Comps
- Natera
Natera Valuation Multiples
Discover Natera's revenue and EBITDA valuation multiples, acquisitions, and investment history, alongside public comparables like GE HealthCare, Illumina, Agilent, Quest Diagnostics and more.
Natera Overview
About Natera
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier’s children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.
Founded
2007
HQ

Employees
4.4K
Website
Financials (LTM)
EV
$30B
Valuation Multiples
Start free trialNatera Financials
Natera reported last 12-month revenue of $3B and negative EBITDA of ($235M).
In the same LTM period, Natera generated $2B in gross profit, ($235M) in EBITDA losses, and had net loss of ($214M).
Revenue (LTM)
Natera P&L
In the most recent fiscal year, Natera reported revenue of $2B and EBITDA of ($221M).
Natera is unprofitable as of last fiscal year, with gross margin of 65%, EBITDA margin of (10%), and net margin of (9%).
Financial data powered by Morningstar, Inc.
Natera Stock Performance
Natera has current market cap of $31B, and enterprise value of $30B.
Market Cap Evolution
Natera's stock price is $218.81.
Natera share price decreased by 2.0% in the last 30 days, and increased by 29.5% in the last year.
Natera has an EPS (earnings per share) of $-1.45.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $30B | $31B | -2.0% | -2.0% | 9.4% | 29.5% | $-1.45 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialNatera Valuation Multiples
Natera trades at 12.1x EV/Revenue multiple, and (129.7x) EV/EBITDA.
EV / Revenue (LTM)
Natera Financial Valuation Multiples
As of June 2, 2026, Natera has market cap of $31B and EV of $30B.
Natera has a P/E ratio of (146.2x).
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Natera Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


Natera Margins & Growth Rates
Natera grew revenue by 21% but EBITDA decreased by 14% in the last fiscal year.
In the most recent fiscal year, Natera reported gross margin of 65%, EBITDA margin of (10%), and net margin of (9%).
Natera Margins
Natera Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
Natera Operational KPIs
Natera's revenue per employee in the last FY averaged $0.5M, while opex per employee averaged $0.4M for the same period.
Natera's Rule of 40 is 15% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Natera's Rule of X is 46% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Data powered by FactSet, Inc. and Morningstar, Inc.
Natera Competitors
Natera competitors include GE HealthCare, Illumina, Agilent, Quest Diagnostics, Labcorp, Exact Sciences, Guardant Health, Hologic, United Imaging and Roche.
Most Natera public comparables operate across Diagnostics & Genomics, Medical Imaging & Diagnostics, BioTech, DeepTech and HealthTech.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| 1.8x | 1.7x | 9.7x | 9.9x | |||
| 6.0x | 5.9x | 18.0x | 21.1x | |||
| 5.7x | 5.6x | 20.0x | 19.0x | |||
| 2.5x | 2.4x | 12.5x | 12.2x | |||
| 2.0x | 1.9x | 11.4x | 11.1x | |||
| - | - | - | - | |||
| 18.1x | 15.8x | (79.9x) | (87.5x) | |||
| - | - | - | - | |||
This data is available for Pro users. Sign up to see all Natera competitors and their valuation data. Start Free Trial | ||||||
Natera VC Funding History
Before going public, Natera raised $110M in total equity funding, across 2 rounds.
Natera Funding Rounds
Acquisitions by Natera
Natera has acquired 1 company to date.
Last acquisition by Natera was on December 4th 2025. Natera acquired Foresight Diagnostics for $275M (EV/Revenue multiple available to Pro users).
Latest Acquisitions by Natera
| Description | Foresight Diagnostics is a Boulder-based developer of the RaDaR assay, a liquid biopsy test measuring minimal residual disease in blood cancers via patient-specific DNA sequencing. The platform detects circulating tumor DNA with high sensitivity for lymphoma and multiple myeloma monitoring. It has secured partnerships with pharmaceutical firms like Bristol Myers Squibb and Genentech for clinical trials. Founded in 2017 as a spinout from University of Colorado, Foresight operates CLIA-certified labs processing thousands of samples annually. |
| HQ Country | |
| HQ City | Denver, CO |
| Deal Date | 4 Dec 2025 |
| Valuation | $275M |
| EV/Revenue | |
| EV/EBITDA | |
This data is available for Pro users. Sign up to see all Natera acquisitions and their M&A valuation multiples. Start Free Trial | |
Investments by Natera
Natera has invested in 1 company to date.
Latest investment by Natera was on December 11th 2025. Natera invested in Myome in their Undisclosed stage round.
Latest Investments by Natera
| Description | Myome is a genomics platform that sequences and analyzes whole genomes for disease risk identification. Users store data in a portable format accessible via HIPAA-compliant cloud for lifelong reuse in research matching. Processing occurs at CLIA-certified labs in the US, covering 100 million genetic variants. Founded in 2020 and based in Boston, Myome partners with 23andMe for ancestry-linked health insights. | Myome is a genomics platform that sequences and analyzes whole genomes for disease risk identification. Users store data in a portable format accessible via HIPAA-compliant cloud for lifelong reuse in research matching. Processing occurs at CLIA-certified labs in the US, covering 100 million genetic variants. Founded in 2020 and based in Boston, Myome partners with 23andMe for ancestry-linked health insights. |
| HQ Country | ||
| HQ City | San Francisco, CA | San Francisco, CA |
| Deal Date | 11 Dec 2025 | 21 Jun 2022 |
| Round | Undisclosed stage | Series B |
| Raised | undisclosed | $23M |
| Investors | Duquesne Family Office; Illumina; Natera; Sequoia Capital | Foresite Capital; Founders Fund; Healthcare Venture Partners; HOF Capital; Natera; Norwest; Sequoia Capital; SoftBank Group |
| Valuation | undisclosed | undisclosed |
| EV/Revenue | ||
| EV/EBITDA | ||
This data is available for Pro users. Sign up to see all Natera investments and their VC round multiples. Start Free Trial | ||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Natera
| When was Natera founded? | Natera was founded in 2007. |
| Where is Natera headquartered? | Natera is headquartered in United States. |
| How many employees does Natera have? | As of today, Natera has over 4K employees. |
| Who is the CEO of Natera? | Natera's CEO is Steven Leonard Chapman. |
| Is Natera publicly listed? | Yes, Natera is a public company listed on Nasdaq. |
| What is the stock symbol of Natera? | Natera trades under NTRA ticker. |
| When did Natera go public? | Natera went public in 2015. |
| Who are competitors of Natera? | Natera main competitors include GE HealthCare, Illumina, Agilent, Quest Diagnostics, Labcorp, Exact Sciences, Guardant Health, Hologic, United Imaging, Roche. |
| What is the current market cap of Natera? | Natera's current market cap is $31B. |
| What is the current revenue of Natera? | Natera's last 12 months revenue is $3B. |
| What is the current revenue growth of Natera? | Natera revenue growth (NTM/LTM) is 20%. |
| What is the current EV/Revenue multiple of Natera? | Current revenue multiple of Natera is 12.1x. |
| Is Natera profitable? | No, Natera is not profitable. |
| What is the current EBITDA of Natera? | Natera has negative EBITDA and is not profitable. |
| What is Natera's EBITDA margin? | Natera's last 12 months EBITDA margin is (9%). |
| What is the current EV/EBITDA multiple of Natera? | Current EBITDA multiple of Natera is (129.7x). |
| What is the current FCF of Natera? | Natera's last 12 months FCF is $12M. |
| What is Natera's FCF margin? | Natera's last 12 months FCF margin is 0%. |
| What is the current EV/FCF multiple of Natera? | Current FCF multiple of Natera is 2630.2x. |
| How many companies Natera has acquired to date? | As of June 2026, Natera has acquired 1 company. |
| What was the largest acquisition by Natera? | $275M acquisition of Foresight Diagnostics on 4th December 2025 was the largest M&A Natera has done to date. |
| What companies Natera acquired? | Natera acquired Foresight Diagnostics. |
| In how many companies Natera has invested to date? | As of June 2026, Natera has invested in 1 company. |
| What was the last Natera investment? | On 11th December 2025 Natera invested in Myome, participating in a Undisclosed stage round, alongside Duquesne Family Office, Illumina, and Sequoia Capital. |
| In what companies Natera invested in? | Natera invested in Myome. |
See public comps similar to Natera
Lists including Natera
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.
